This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Use of peritoneal dialysis or haemodialysis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Haemodialysis is significantly more efficient than peritoneal dialysis (CAPD) at removing solutes from the blood. However, there may be difficulty with:

  • vascular access
  • cardiovascular stability - especially, in patients who may be elderly, hypotensive, or have a recent history of myocardial infarction

The efficiency of peritoneal dialysis is constrained by the volume of dialysis fluid used. Volumes greater than two litres are poorly tolerated. Haemodialysis achieves clearance rates of 100 ml/min compared to values of 25-30 ml/min for peritoneal dialysis. Thus, peritoneal dialysis becomes increasingly inadequate with:

  • increasing uraemia
  • increasing body weight

Peritoneal dialysis also may cause respiratory difficulty, even with 1 litre exchanges, and peritonitis remains a major complication. The haemodynamic stresses caused by CAPD are less than for haemodialysis.

NICE guidance states that:

  • offer all people with stage 5 CKD a choice of peritoneal dialysis or haemodialysis, if appropriate, but consider peritoneal dialysis as the first choice of treatment modality for:
    • children 2 years old or younger
    • people with residual renal function
    • adults without significant associated comorbidities

Reference:


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.